alexa Seroconversion of Hbsag in Melanoma Patient with Hepati
ISSN: 2165-7920

Journal of Clinical Case Reports
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Seroconversion of Hbsag in Melanoma Patient with Hepatitis B Treated with Checkpoint Inhibitors: A Case Report

Xizhi Wen#, Ya Ding#, Baoyan Zhu, Dandan Li, Jinjin Li, Yao Wang and Xiaoshi Zhang*

Biotherapy Center, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, P.R China

*Corresponding Author:
Xiaoshi Zhang
Biotherapy Center, State Key Laboratory of Oncology in South China
Sun Yat-sen University Cancer Center, P.R China
Tel: +86 20 86-20-87343383
E-mail: [email protected]

Received Date: April 17, 2017; Accepted Date: April 20, 2017; Published Date: April 25, 2017

Citation: Wen X, Ding Y, Zhu B, Li D, Li J, et al. (2017) Seroconversion of Hbsag in Melanoma Patient with Hepatitis B Treated with Checkpoint Inhibitors: A Case Report. J Clin Case Rep 7:951. doi: 10.4172/2165-7920.1000951

Copyright: © 2017 Wen X, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Based on remarkable and sustained antitumor activity, the anti-CTLA-4 antibody ipilimumab, and anti-PD1 antibodies nivolumab and pembrolizumab have been approved for treatment of advanced melanoma. As checkpoint blockade is associated with potentially serious immune-related adverse events, including autoimmune hepatitis, clinical trials evaluating these agents have excluded patients with chronic hepatitis B virus infection. Herein, we describe one patient with advanced melanoma and concomitant HBV infections experiencing seroconversion of HBsAg after treatment with combination of PD-1 and CTLA-4 blockade.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords